Experience

• 

  UCB

  • Oakville, Ontario, Canada

  • Regional Business Manager, Immunology

    • May 2024 - Present
    • Oakville, Ontario, Canada

• 

  UCB Canada Inc.

  • South West Ontario

  • Biopharmaceutical Territory Manager, Immunology

    • Sep 2020 - May 2024
    • South West Ontario

    • Recipient, UCB Top Performer Award for 2021 & 2022• Achieved record number of HCP engagements (F2F and virtual) in the pandemic era.• Successfully built platforms for meaningful, ongoing, and sustained engagements with key stakeholders.• Developed access & nurtured relationships with previously hard-to-see & no-see stakeholders.• Achieved highest national Cimzia patient enrollment for the dermatology indication.• Significantly improved Cimzia patient enrollment in Rheumatology within 2 months of assuming the territory.• Recognized for SMART, comprehensive and carefully thought-out business plans.

• 

  Verity Pharmaceuticals

  • Toronto and South West Ontario

  • Hospital Account Specialist - Key Accounts

    • Mar 2020 - Sep 2020
    • Toronto and South West Ontario

    • Responsible for the launch and promotion of the injectable antibiotic, Ivozfo• Helped build robust customer data management database• Successfully planned and implemented remote virtual one-on-one meetings with Health Care Professionals• Successfully planned and implemented remote virtual departmental educational event/s• Successfully planned and organized remote virtual ad-boards• Achieved the highest national YTD sales ending August 2020

• 

  Merck

  • United States
  • Pharmaceutical Manufacturing
  • 700 & Above Employee

  • HIV/Hospital Specialty Sales/Key Accounts

    • Oct 2016 - Nov 2019

    •Promoted Isentress. Launched Isentress HD, Pifeltro and Delstrigo to infectious disease specialists, pharmacists, nurses and select primary care physicians. •Successfully gained access with previously “no-see” Infectious Disease physicians and developed them as advocates for the assigned products, Isentress and Doravirine.•Successfully developed peer to peer relationship with key scientific and medical leaders and other stakeholders in HIV.•Reversed fast declining market share for Isentress by effectively identifying and navigating key prescribing barriers. Successfully grew the product by 10% within a year of assuming territory. •Successfully achieved positive growth rate for Isentress in sectors that had previously recorded minus double digit decline rate. •Successfully identified three “easy-win” patient buckets as part of the provincial strategy for Isentress. •Successfully identified gap in the efficacy messaging for Isentress which led to increased uptake for the drug.•Championed creation and development of strategy for Isentress in HIV positive women of child bearing age.•Championed the creation and development of a provincial strategy to neutralize uptake of the new HIV drug, TAF (Tenofovir Alafenamide). Identified both scientific resources and educational initiatives required as part of the strategy. •Coined the marketing tag line “NNRTI that behaves like an INSTI” for the new HIV drug, Doravirine.•Successfully launched Doravirine for the treatment of HIV. Grew Doravirine’s prescription by 200% one-week post ODB listing.•Recipient, 2019 ARCH Community Partner Award for an exemplary working relationship with the organization.

  • Cardiovascular and Diabetes Specialty Sales Representative

    • Sep 2009 - Oct 2016

    •Promoted Januvia, Janumet/XR for type 2 diabetes, Olmetec for hypertension & Ezetrol for hypercholesterolemia.•Successfully gained access with previously “no-see” cardiologists & developed them as strong advocates for Olmesartan and Ezetimibe.•Successfully developed peer to peer relationship with key scientific & medical leaders in diabetes, hypertension & lipids.•Consistently achieved/surpassed sales objectives for the assigned products. •Produced highest national sales volume for Januvia & Olmetec (45M and 15M respectively)•Achieved highest national market share for Januvia & Olmetec (20% and 18% respectively)•Achieved second highest sales volume for Ezetrol in the province•Recipient, Director’s Award of Excellence (Team Category), 2014•Coined marketing tag line “Efficacy without Compromise” for Janumet•Successfully planned & implemented high impact international speaker programs that helped grew regional & national market share for the diabetes & anti-hypertensive portfolio. Boldly liaised with both internal & external global partners to identify the best speakers.•Achieved hospital formulary listing for Januvia in all assigned hospitals & Olmetec in select hospitals. •Implemented one of the most successful disease awareness campaign for Januvia/Janumet•Championed SSR Journal Club which led to major advancement in the scientific expertise of the team. •Identified & recommended relevant publications as part of the promotional tools for the assigned products.•Contributed in content development of medical education programs for diabetes & hypertension•Successfully developed & facilitated soft skill & marketing related workshops at the national & regional meetings.•Facilitated training of new representatives on product portfolio & competitive products. •Developed & implemented a “unified speaker request form” for the three brands (Januvia, Olmetec, Ezetrol) which helped streamline processes & improved work efficiency

  • Medical Science Liaison, Diabetes

    • May 2009 - Sep 2009

    •Successfully developed relationships KOLs within four months of assuming the territory•Contributed to the successful disease awareness campaign for the Sitagliptin franchise

  • Medical Science Liaison/Health Science Associate, Urology

    • Jan 2003 - May 2009

    •Handled medical affairs-related initiatives for the Urology franchise (finasteride for benign prostatic hyperplasia (BPH) indication and prostate cancer prevention•Planned and implemented groundbreaking, non-traditional and highly impactful national speaker programs and lecture series that helped address questions/concerns surrounding landmark trial in prostate cancer prevention. Liaised and partnered with global scientific experts (where previously there was none) in the development of the national educational initiatives.•Effectively helped develop foundation for successful re-launch of finasteride for treatment of benign prostatic hyperplasia. •Authored/Drafted rebuttal paper on finateride for benign prostatic hyperplasia which was used as guiding document for external scientific communication.•Led creation and development of scientific platform for finasteride in prostate cancer prevention.•Championed the creation and development of key national discussion slide decks for dissemination.•Helped shape and develop content of health education materials for finasteride•Consistently led group in identifying key scientific materials to help support scientific discussions.•Provided both technical and therapeutic coaching and support to MSL colleagues.•Developed administrative templates and forms to streamline work and improve work efficiencies.•Recipient, Director’s Award of Excellence, 2004, 2005•Finalist, Director’s Award of Excellence, 2006

  • Medical Science Liaison/Health Science Associate, Neurology

    • Aug 2002 - Jan 2003

    •Handled scientific and medical affairs related initiatives for the migraine headache franchise involving Rizatriptan•Successfully developed peer-to-peer partnership with national experts in migraine and headache management within five months of assuming the territory.•Successfully planned and implemented educational events within a short of time of assuming the territory

  • Therapeutic Area Specialist

    • May 1998 - Aug 2002

    •Promoted Propecia for male patter hair loss, Timotic, Trusopt and Cosopt for glaucoma and Maxalt for migraine•Successfully launched Finasteride (Propecia) for male pattern hair loss. Achieved the highest YTD sales at 139% at the year of launch.•Recognized for running the most successful disease awareness campaign for Propecia which led to outstanding sales•Recipient, “Directors’ Award of Excellence” 1999.•Consistently achieved sales above 100% for all the assigned products.•Established strong ties with key thought leaders.•Created a winning demographic-based business plan that won adoption by the national sales manager•Developed template for the team’s business plan.•Successfully planned and implemented CMEs/International Distinguished Lecture Series. •Provided training and ongoing coaching new sales representatives.

• 

  VOCO GmbH

  • Ontario

  • Sales Executive, Dental

    • Dec 1997 - May 1998
    • Ontario

    •Led Voco business expansion in Canada•Developed partnerships with local dental suppliers and distributors •Trained supplier representatives on the product offerings of the company•Conducted product awareness campaign throughout Ontario•Called on dentists and denturists throughout the province•Conducted In-service product presentations to dental offices and denturists and supplier representatives

• 

  GSK

  • Disease Awareness Specialist, Oncology, Neuroscience (Migraine), Anesthesia

    • 1993 - 1997

    •Championed "post operative nausea and vomiting" disease awareness campaign•Launched and promoted Ondansetron (Zofran) for post operative nausea and vomiting•Recognized for a successful disease awareness campaign for Ondansetron (Zofran) for the indication post-operative nausea and vomiting•Promoted Ondansetron (Zofran) for chemotherapy and radiotherapy induced emesis•Tripled sales of Ondansetron (Zofran) for chemo-radiotherapy induced emesis indication in Southern Philippines within three months of assuming the ter•Promoted Sumatriptan (Imitrex) for migraine headache•Tripled sales volume of the Ondansetron (Zofran) for chemo-radiotherapy induced emesis indication in Southern Philippines within three months of assuming the territory.•Successfully organized cancer patient support groups in key hospitals throughout the country•Successfully expanded marker share for Sumatriptan (Imitrex) by identifying other target specialties. These initiatives led to a 50% increase in sales for the brand.•Successfully organized headache camps in key centers•Negotiated profitable strategic alliances with oncology and anesthesia-based companies for joint sales efforts.•Gained Drug Formulary Approval for the assigned products.

  • Medical Sales Representative

    • 1990 - 1993

    •Promoted the following therapeutic lines: Anti-allergy/Immunology (Cetirizine), Gastrointestinal (Ranitidine), Respiratory(Salbutamol and Beclomethasone inhalers), Anti-infectives (Cephalexin, Ceftizidime, Cefuroxime), and Dermatologicals (Eumovate, Betnovate, Dermovate)•Earned “General Manger’s Sales Excellence Award” 1992, 1993•Secured business with previously “no see” physicians•Consistently outsold major competition despite higher cost our products•Doubled antibiotic sales within five months of assuming the territory•Designed and implemented prescription tracking which paved the way for more efficient customer segmentation and targeting